Gustave Roussy Immune Score in Nivolumab Treated Metastatic Renal Cell Carcinoma

Abstract

Aim: The aim of this study is to evaluate the Gustave Roussy immune (GRIm) score as a biomarker for survival in metastatic renal cell carcinoma (mRCC) patients receiving nivolumab following first-line treatment. Material and Method: 41 mRCC patients who were given nivolumab beyond first line were included in this retrospective study. Data on ratio of neutrophile to lymphocyte, albumin, and LDH levels were utilized to determine GRIm score. Patients scoring 2–3 were grouped into the high GRIm score, whereas those scoring 0–1 were grouped as the low GRIm score. The association between the GRIm score and progression-free survival (PFS) with overall survival (OS) was examined. Results: Thirty patients exhibited a low GRIm score, whereas eleven presented a high GRIm score. Prolonged median PFS and OS, with values of 7.06 months compared to 2.89 months (p=0.002) and 20.34 months compared to 4.27 months (p<0.001), are found respectively in low GRIm score group. In terms of PFS, a higher GRIm score was identified as an independent prognostic indicator but lacked prognostic significance for OS in multivariable analysis. Conclusion: The GRIm score may be used as an accessable and cost-effective prognostic biomarker in mRCC patients receiving nivolumab, and may assist clinicians in patient selection, thus improving therapeutic efficacy and the efficient use of clinical resources.

Keywords

• Renal cell carcinoma
• metastatic
• Gustave Roussy immune score
• nivolumab
• prognosis

Kaynakça

1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-31.
3. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-13.
4. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277-90.
5. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116-27.
6. Powles T, Albiges L, Bex A, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692-706.
7. Sarkis J, Assaf J, Alkassis M. Biomarkers in renal cell carcinoma: towards a more selective immune checkpoint inhibition. Transl Oncol. 2021;14:101071.
8. Rebuzzi SE, Perrone F, Bersanelli M, et al. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Mol Diagn. 2020;20:169-85.

9. Ishihara H, Tachibana H, Takagi T, et al. Predictive impact of peripheral blood markers and c-reactive protein in nivolumab therapy for metastatic renal cell carcinoma. Target Oncol. 2019;14:453-63.
10. Rebuzzi SE, Signori A, Banna GL, et al. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol. 2021;13:17588359211019642. Erratum in: Ther Adv Med Oncol. 2021;13:17588359211036552.
11. Gu L, Ma X, Wang L, et al. Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma and construction of a predictive model. Oncotarget. 2017;8:52094-103.
12. Yano Y, Ohno T, Komura K, et al. Serum C-reactive protein level predicts overall survival for clear cell and non-clear cell renal cell carcinoma treated with ipilimumab plus nivolumab. Cancers (Basel). 2022;14:5659.
13. Bigot F, Castanon E, Baldini C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer. 2017;84:212-8.
14. Nakazawa N, Sohda M, Endo M, et al. The Gustave Roussy Immune score is a powerful biomarker for predicting therapeutic resistance to chemotherapy in gastric cancer patients. Cancer Chemother Pharmacol. 2024;94:517-22.
15. Tian S, Cao Y, Duan Y, Liu Q, Peng P. Gustave Roussy Immune Score as a novel prognostic scoring system for colorectal cancer patients: a propensity score matching analysis. Front Oncol. 2021;11:737283.
16. Li SJ, Zhao L, Wang HY, et al. Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: a propensity score matching retrospective cohort study. Int J Surg. 2020;84:25-40.
17. Minami S, Ihara S, Komuta K. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score are prognostic markers for extensive disease of small cell lung cancer. World J Oncol. 2020;11:98-105.
18. Feng JF, Wang L, Yang X, Chen S. Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma. J Cancer. 2020;11:1334-40.
19. Li Y, Pan Y, Lin X, et al. Development and validation of a prognostic score for hepatocellular carcinoma patients in immune checkpoint inhibitors therapies: the hepatocellular carcinoma modified Gustave Roussy Immune Score. Front Pharmacol. 2021;12:819985.
20. Kim SH, Kwon WA, Kim S, et al. The neutrophil-to-lymphocyte ratio makes the Heng risk model improve better the prediction of overall survival in metastatic renal cell cancer patients. Jpn J Clin Oncol. 2018;48:835-40.
21. Zhang N, Zhang H, Zhu D, et al. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. Int J Surg. 2020;79:66-73.
22. Kucharz J, Dumnicka P, Giza A, et al. Radiological response and neutrophil-to-lymphocyte ratio as predictive factors for progression-free and overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Adv Exp Med Biol. 2019;1153:31-45.